ArticleOphthalmology2026
Ophthalmic Drug Shortages in the United States: Survey of the University of Utah Drug Information Service Drug Shortage Database.
Article in Ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Medicine shortages and glaucoma care: a time-series analysis indicating population-level consequences of a national timolol eye drop shortage.International journal of clinical pharmacy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeTo survey ophthalmic drug shortages in the United States from 2001 through 2024.
designRetrospective database review. SUBJECTS: Patient data were sourced from the University of Utah Drug Information Service (UUDIS) national database.
main outcome measuresThe UUDIS drug shortage reports from 2001 through 2024 were reviewed, and shortages resulting from drug discontinuation, business decision, or duration of 1 day or less were excluded from analysis. The remaining 3086 drug shortage reports from 2001 through 2024 were reviewed by a panel of 4 ophthalmologists and 1 clinical pharmacist.
methodsDrugs used in ophthalmology were highlighted, and their clinical applications were established. Drug delivery route (local vs. systemic), the cause of the shortage, the duration of the shortage, and whether the drug was patent protected during the shortage were assessed.
resultsOf 3086 shortage reports, 379 reports were of ophthalmic medications, of which 329 shortages had resolved and 50 remained active as of June 2024. On average, ophthalmic medications accounted for 15% of active shortages at any given time. Systemic and locally delivered medications were represented equally; most shortages were of anti-infective medications (35%) and steroids (26%). The leading causes of ophthalmic medication shortages were unknown (63%), manufacturing problems (20%), and supply and demand mismatch (10%). Median duration of ophthalmic medication shortage was 326 days (interquartile range [IQR], 145-695 days), nearly 30 days longer than the median duration for all drugs (298 days; IQR, 111-619; P = 0.023). Mean shortage duration of ophthalmic medications that were patent protected during each shortage was significantly less (184 days; IQR, 48-422 days) than medications that experienced a shortage while off-patent (359 days; IQR, 164-755 days; P < 0.0001).
conclusionsOphthalmic drug shortages constitute a significant portion of total drug shortages, the median shortage length is greater than that for all medications, and shortage duration is influenced by patent status. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.